valsartan has been researched along with Hyperlipemia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Beom, JW; Cho, YH; Jang, JY; Kang, SM; Kim, JS; Kim, WH; Lee, KJ; Ryu, JK; Shin, WY; Yoon, YW | 1 |
| Palmer, OM; Rhoads, DD; Sivak, RA | 1 |
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kitabata, H; Kuroi, A; Mochizuki, S; Muragaki, Y; Takarada, S; Tanimoto, T; Tsujioka, H; Yoshida, K | 1 |
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Shiomi, M; Tsujioka, A; Tsujioka, H; Yoshida, K | 1 |
| Endo, K; Koide, N; Miyashita, Y; Murano, T; Ohira, M; Oyama, T; Saiki, A; Shirai, K | 1 |
| Glazer, R; Jia, Y; Kariisa, M; Pitt, B; Prescott, MF; Radauceanu, A; Rajagopalan, S; Zannad, F | 1 |
2 trial(s) available for valsartan and Hyperlipemia
| Article | Year |
|---|---|
The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypertension; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2006 |
Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.
Topics: Antihypertensive Agents; Biomarkers; Blood Pressure Monitoring, Ambulatory; C-Reactive Protein; Chemokine CCL2; Double-Blind Method; Drug Combinations; Drug Synergism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Simvastatin; Tetrazoles; Valine; Valsartan | 2007 |
4 other study(ies) available for valsartan and Hyperlipemia
| Article | Year |
|---|---|
Effectiveness and Safety of a Fixed-Dose Combination of Valsartan and Rosuvastatin (Rovatitan
Topics: Antihypertensive Agents; Cholesterol, LDL; Humans; Hyperlipidemias; Hypertension; Rosuvastatin Calcium; Treatment Outcome; Valsartan | 2023 |
Plasma abnormalities following overdose.
Topics: Color; Diltiazem; Drug Overdose; Fat Emulsions, Intravenous; Female; Food-Drug Interactions; Hemolysis; Humans; Hyperlipidemias; Middle Aged; Off-Label Use; Plasma; Poisoning; Tetrazoles; Valine; Valsartan | 2014 |
Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
Topics: Acetylcholine; Amides; Animals; Antihypertensive Agents; Atherosclerosis; Biopterins; Blood Pressure; Drug Therapy, Combination; Endothelium, Vascular; Fumarates; Heart Rate; HSP90 Heat-Shock Proteins; Hyperlipidemias; Inflammation Mediators; Lipids; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rabbits; Renin; Tetrazoles; Tyrosine; Valine; Valsartan; Vasodilation; Vasodilator Agents | 2008 |
Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Biological Availability; Drug Therapy, Combination; Echocardiography; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Nitric Oxide; Quinolines; Rabbits; Reactive Oxygen Species; Tetrazoles; Tyrosine; Valine; Valsartan | 2008 |